Curtis P Mcmurtrey

US Patent:

20130131573, May 23, 2013

Filed:

Apr 30, 2012

Appl. No.:

13/460433

Inventors:

William H. Hildebrand - Edmond OK, US
Rico Buchli - Edmond OK, US
Curtis McMurtrey - Moore OK, US
Steven Cate - Moore OK, US

International Classification:

A61M 1/30

US Classification:

604 604, 530403

Abstract:

An anti-MHC removal device includes a serologically active, soluble MHC moiety covalently coupled to a solid support. Methods of production include covalently coupling the serologically active, soluble MHC moiety to the solid support. Methods of use of the anti-MHC removal device include contacting a biological sample with the device so that antibodies specific for the MHC moiety are removed from the biological sample. The biological sample is then recovered.

US Patent:

20130245385, Sep 19, 2013

Filed:

Apr 11, 2013

Appl. No.:

13/860897

Inventors:

William H. Hildebrand - Edmond OK, US
Curtis McMurtrey - Oklahoma City OK, US
Rico Buchli - Edmond OK, US
Steven Cate - Moore OK, US

Assignee:

THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA - Norman OK

International Classification:

C07K 16/28
B01D 15/00

US Classification:

600300, 5303896, 210483

Abstract:

An anti-MHC removal device includes a serologically active, soluble MHC moiety covalently coupled to a solid support. Methods of production include covalently coupling the serologically active, soluble MHC moiety to the solid support. Methods of use of the anti-MHC removal device include contacting a biological sample with the device so that antibodies specific for the MHC moiety are removed from the biological sample.

US Patent:

20070099182, May 3, 2007

Filed:

Nov 1, 2006

Appl. No.:

11/591118

Inventors:

William Hildebrand - Edmond OK, US
Angela Wahl - Oklahoma City OK, US
Curtis McMurtrey - Oklahoma City OK, US

International Classification:

C12Q 1/70
C12Q 1/68
C07K 7/08
C07K 7/06

US Classification:

435005000, 435006000, 435456000, 435325000, 530328000, 530329000, 530330000

Abstract:

The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class 11 MHC molecules which may be from uninfected, infected, or tumorigenic cells. The methodology of the present invention broadly allows for these peptide ligands and their cognate source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorigenic versus nontumorigenic cells, with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.

US Patent:

20150273039, Oct 1, 2015

Filed:

Mar 27, 2015

Appl. No.:

14/671322

Inventors:

- NORMAN OK, US
Curtis McMurtrey - Oklahoma City OK, US
David Lewinsohn - Portland OR, US
Deborah Lewinsohn - Portland OR, US
Melanie Harriff - Portland OR, US

International Classification:

A61K 39/04
G01N 33/569

Abstract:

Compositions that include at least one isolated, class I HLA trimolecular complex that includes a peptide ligand unique to -infected cells are disclosed. Isolated compositions that include the three components of the trimolecular complex and/or a polynucleotide encoding one or more of the three components are also disclosed.